CD19 and leukemia: Similar to results observed for CD19-specific CAR-NK, this CD20-specific CAR NK-92 showed noticeably enhanced cytotoxicity against CD20-positive malignant cells including the cancer cells resistant to primary NK cells in primary lymphoma and leukemia cells while remained non-toxic to CD20-negative cells with expression of CD20 [140] (109).